

Contact: Hariharan Subramanian
CytoSolve, Inc.
Phone: (617) 553-1015
701 Concord Avenue
Cambridge, MA 02138
info@cytosolve.com
www.cytosolve.com



PRESS RELEASE

CytoSolve and MD Anderson Cancer Center join hands to advance cure strategies for pancreatic cancer

Cambridge, June 30, 2015: CytoSolve and the University of Texas MD Anderson Cancer center (MDACC) have finalized an agreement that will enable acceleration of therapeutics for pancreatic cancer.

PancreaSolve is a new joint venture with MD Anderson Cancer Center for advancing a broad range of therapeutics for pancreatic cancer. The key scientists include Dr. V.A. Shiva Ayyadurai, Dr. Sunil Krishan and Dr. Anirban Maitra. Dr. Ayyadurai is world-renowned systems biologist, also recognized as the inventor of email. Dr. Ayyadurai holds four degrees from M.I.T., including his doctorate in systems biology. Dr. Sunil Krishan is a board-certified oncologist and a world renowned cancer researcher at MD Anderson Cancer Center and is actively involved in the in vitro and in vivo research. Dr. Anirban Maitra is a world renowned cancer researcher from MD Anderson Cancer Center and brings in valuable domain expertise in the area of pancreatic cancer research.

CytoSolve is headquartered in Cambridge, MA. CytoSolve's revolutionary technology for in silico mechanistic modeling is accelerating discovery and development of single and multi-combination therapeutics.

The University of Texas MD Anderson Cancer Center is one of the world's most respected centers devoted exclusively to cancer patient care, research, education and prevention. It is a premier cancer center in the world, based on the excellence in research-driven patient care and cutting-edge science.